On November 3, 2023 NKILT Therapeutics, Inc., a preclinical-stage cell therapy biotech company developing proprietary Chimeric ILT-Receptor (CIR)–engineered natural killer (NK) cell therapies, reported that preclinical data of the CIRNK cells have been selected for an oral presentation at the 65th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, being held December 9-12, 2023, and for poster presentation at the 38th Society of Immunotherapy for Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, being held November 1-5, 2023 (Press release, NKILT Therapeutics, NOV 3, 2023, View Source [SID1234636924]). Both events are taking place at the San Diego Convention Center in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SITC (Free SITC Whitepaper) 2023 presentation will highlight the latest updates on NKILT Therapeutics’ engineered CIRNK cells proof-of-concept in vitro data against leukemia cells expressing human leukocyte antigen G (HLA-G).

The ASH (Free ASH Whitepaper) 2023 oral presentation will feature details of the proprietary activation domains that enhance activity of the CIRNK engineered cells against HLA-G-positive acute myeloid leukemia (AML) cells. This presentation will expand preclinical data with a specific focus on these novel activation domains and will characterize the serial killing activity against AML cells. These data illustrate the potential of the CIR technology, associated with proprietary activation domains, to enhance engineered NK cells’ direct and innate killing activity against leukemia cells.

"Today’s poster presentation at SITC (Free SITC Whitepaper) 2023 and the oral presentation at the upcoming ASH (Free ASH Whitepaper) 2023 Annual Meeting confirm the great progress we have made in the development of our unique engineered CIRNK cells, which allows us to remain on track to name our lead assets to launch our IND process later this year," emphasized Raphaël G. Ognar, President & CEO, Co-founder of NKILT Therapeutics, Inc.

Details of the presentations:

Poster presentation – 38th SITC (Free SITC Whitepaper) Annual Meeting, San Diego, November 2-5, 2023
Title: Targeting HLA-G positive tumors with engineered Natural Killer cells expressing a Chimeric ILT Receptor (CIR)
Presenter: MyLinh Duong, PhD
Poster Display Date & Time: Friday, November 3, 2023, 9:00 am-7:00 pm PDT
Abstract Number: 251
Location: San Diego Convention Center, Ground Level, Exhibit Halls A and B1

Oral presentation – 65th ASH (Free ASH Whitepaper) Annual Meeting & Exposition, San Diego, December 9-12, 2023
Title: Engineered Natural Killer Cells Expressing Chimeric ILT Receptors (CIR) Effectively Target HLA-G-Positive AML Tumor Cells.
Presenter: J. Henri Bayle, PhD
Presentation Date & Time: Sunday, December 10, 2023, 10:30 am PDT
Session Name: 703. Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies
Session Time: 9:30-11:00 am PDT
Abstract Number: 467
Location: San Diego Convention Center, Room 6A

"We are very pleased to present our findings on the development of CIRNK cells targeting HLA-G at SITC (Free SITC Whitepaper) and the further augmentation of CIRNK cell anti-AML efficacy at ASH (Free ASH Whitepaper). We are very proud of the work delivered by our team," said J. Henri Bayle, PhD, CTO/CDO & Co-founder of NKILT Therapeutics, Inc.

About Chimeric ILT-Receptor (CIR) Technology

Chimeric ILT Receptor, or CIR, technology utilizes engineered proteins designed to provide activating signals to immune cells in response to engagement of the tumor-enriched immunosuppressing protein human leukocyte antigen G (HLA-G) with extracellular binding domains derived from ILT2 or ILT4, the natural inhibitory receptors of HLA-G. This technique converts HLA-G from an agent for tumor immune evasion into a target protein for immunotherapy. The use of a CIR engager permits targeting of the several isoforms of HLA-G that can be expressed by tumors.